Sonoma Biotherapeutics Collaborated with Regeneron to Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
Shots: Sonoma to receive $75M up front incl. $45M in cash & $30M in equity inv...
Shots: Sonoma to receive $75M up front incl. $45M in cash & $30M in equity inv...
Shots: The companies collaborated to identify biomarkers of response to Onconova&r...
Shots: Nurix will receive $20M in option exercise fees and receive an additional ~...
Shots: PeptiDream to receive up-front, research funding & success-based milest...
Shots: The companies have decided to expand their existing collaboration for RNA i...
Shots: ImmunoGen will receive $15M up front, ~$337M per target in option exercise...
Incisive News in 3 Shots.